KC
SLNO

Kepos Capital’s Soleno Therapeutics SLNO Stock Holding History

Kepos Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,506
Closed -$81K – 398
2018
Q3 		$81K Hold
2,506
– – ﹤0.01% 336
2018
Q2 		$88K Buy
+2,506
New +$73.5K ﹤0.01% 323

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Kepos Capital's SLNO Position: Q4 2018 in Review

Kepos Capital sold out of Soleno Therapeutics (SLNO) in Q4 2018, closing a stake of 2,506 shares — an estimated $81K sold.

Kepos Capital first reported a position in SLNO in Q2 2018 and held it in 2 quarters. The position peaked at $88K in Q2 2018. 19 funds tracked by Wall St. Rank hold SLNO as of Q4 2018.

  • Kepos Capital reported no remaining Soleno Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kepos Capital sold 2,506 Soleno Therapeutics shares in Q4 2018, an estimated $81K.
  • Kepos Capital first reported a position in Soleno Therapeutics in Q2 2018 and held it in 2 quarters.
  • Kepos Capital's Soleno Therapeutics position peaked at $88K in Q2 2018.
  • 19 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2018.

Based on Kepos Capital's 13F filing for Q4 2018, filed 13 Feb 2019.